Chile’s lower house of congress has backed a resolution calling for the government to set the scene for the compulsory licensing of hepatitis C drugs.
Pressure is again mounting on the Chilean government to take measures that would allow generic versions of hepatitis C drugs formulated with Gilead Sciences Inc.’s sofosbuvir to enter the market. Law makers in the country’s lower house of Congress have backed a resolution calling on the government to move ahead with issuing compulsory licenses.
On Jan. 2, the chamber of deputies voted in support of resolution 1014, which calls on the health minster to...
The Philippines medicines regulator explains how it intends to implement the ASEAN mutual recognition agreement under which member states have committed to accept bioequivalence study reports for generics issued by approved BE centers.
Private Company Edition: June’s eight $100m-plus venture capital rounds already outpace the seven each raised in March, April and May, including €255m ($274.2m) for ITM and $200m for Upstream, but while there were five $25m or less VC financings during the past week, mid-sized deals were lacking.
Novartis continues to fight tooth and nail to protect its $3bn Entresto brand in the US following the latest FDA approval of a generic version.
A US FDA analysis found that facility inspection issues were the fastest growing factor in the recent rise of complete response letters for biologics licensing applications, in part reflecting the limitations of single-product inspections at contract facilities manufacturing multiple products.
Novartis continues to fight tooth and nail to protect its $3bn Entresto brand in the US following the latest FDA approval of a generic version.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
